NCT07680946Phase 2Recruiting

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Study sponsor: TG Therapeutics, Inc. · TGTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-12-12Estimated
Enrollment · participants60Estimated
Source updated2026-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.